Targeting a specific protein to improve treatment for blood disorders
Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms
This study is looking at how a protein called SHP2 affects treatments for blood disorders called myeloproliferative neoplasms (MPNs), with the goal of creating better drugs that can help patients feel better and possibly achieve remission.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10788293 on NIH RePORTER |
What this research studies
This research focuses on classical myeloproliferative neoplasms (MPNs), which are serious blood disorders affecting around 300,000 people in the U.S. The study investigates how a protein called SHP2 interacts with JAK2 inhibitors, which are currently used to manage MPN symptoms but do not lead to remission. By developing new drugs that can keep SHP2 inactive, the research aims to overcome drug resistance and improve treatment outcomes for patients. The approach involves understanding how MPN cells respond to existing therapies and finding ways to enhance their effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with classical myeloproliferative neoplasms who have not achieved remission with current therapies.
Not a fit: Patients with other types of blood disorders or those who have not been diagnosed with myeloproliferative neoplasms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with myeloproliferative neoplasms, potentially improving their quality of life and survival rates.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other blood disorders, suggesting that this approach could be effective, although it is still relatively novel in the context of MPNs.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Reuther, Gary W — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Reuther, Gary W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.